Cargando…

N6-Methyladenosine Modification of LncRNA DUXAP9 Promotes Renal Cancer Cells Proliferation and Motility by Activating the PI3K/AKT Signaling Pathway

Most localized human renal clear cell carcinoma (ccRCC)-related deaths result from cancer recurrence and metastasis. However, the precise molecular mechanisms largely remain unknown. In recent years, an increasing number of long noncoding RNAs (lncRNAs) have been shown to be vital regulators of tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Lei, Tang, Yiming, Li, Hongbo, Li, Pengju, Ye, Yunlin, Cen, Junjie, Gui, Chengpeng, Luo, Junhang, Cao, Jiazheng, Wei, Jinhuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217835/ https://www.ncbi.nlm.nih.gov/pubmed/34168980 http://dx.doi.org/10.3389/fonc.2021.641833

Ejemplares similares

The LncRNA DUXAP10 Could Function as a Promising Oncogene in Human Cancer
por: Zhao, Junjie, et al.
Publicado: (2022)

LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway
por: Lei, Changjiang, et al.
Publicado: (2022)

Therapeutic implications for localized prostate cancer by multiomics analyses of the ageing microenvironment landscape
por: Gui, Chengpeng, et al.
Publicado: (2023)

LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis
por: Wang, Yongfeng, et al.
Publicado: (2022)

microRNA‐1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39‐mediated PI3K/AKT/mTOR pathway in HCC
por: Sun, Liankang, et al.
Publicado: (2019)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
por: Li, Pengju, et al.
Publicado: (2021)

Downregulated DUXAP8 lncRNA impedes trophoblast cell proliferation and migration by epigenetically upregulating TFPI2 expression
por: Tang, Xiaotong, et al.
Publicado: (2023)

Silencing lncRNA DUXAP8 inhibits lung adenocarcinoma progression by targeting miR-26b-5p
por: Liu, Yi, et al.
Publicado: (2021)

lncRNA DUXAP8 Facilitates Multiple Malignant Phenotypes and Resistance to PARP Inhibitor in HCC via Upregulating FOXM1
por: Hu, Yu, et al.
Publicado: (2020)

LncRNA-DUXAP8 Regulation of the Wnt/β-Catenin Signaling Pathway to Inhibit Glycolysis and Induced Apoptosis in Acute Myeloid Leukemia
por: Zhai, Hong, et al.
Publicado: (2021)

Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma
por: Pan, Yihui, et al.
Publicado: (2023)

Localization of external urethral orifice in coronary sulcus during urethroplasty in case of severe hypospadias accompanied by prostatic utricle cyst
por: Lu, Jun, et al.
Publicado: (2021)

Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de‐palmitoylation
por: Shi, Zhehao, et al.
Publicado: (2023)

DUXAP8, a pseudogene derived lncRNA, promotes growth of pancreatic carcinoma cells by epigenetically silencing CDKN1A and KLF2
por: Lian, Yifan, et al.
Publicado: (2018)

LncRNA DUXAP9‐206 directly binds with Cbl‐b to augment EGFR signaling and promotes non‐small cell lung cancer progression
por: Zhu, Ting, et al.
Publicado: (2018)

Overexpressed pseudogenes, DUXAP8 and DUXAP9, promote growth of renal cell carcinoma and serve as unfavorable prognostic biomarkers
por: Chen, Jing, et al.
Publicado: (2019)

Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia
por: Zhang, Li, et al.
Publicado: (2022)

Pseudogene DUXAP10 acts as a diagnostic and prognostic marker and promotes cell proliferation by activating PI3K/AKT pathway in hepatocellular carcinoma
por: Yue, Chaosen, et al.
Publicado: (2019)

DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways
por: Han, Kun, et al.
Publicado: (2019)

SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
por: Li, Pengju, et al.
Publicado: (2020)

A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR
por: Liu, Hongmei, et al.
Publicado: (2020)

Regulation of lncRNA expression
por: Wu, Zhuomin, et al.
Publicado: (2014)

N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients
por: Song, Wei, et al.
Publicado: (2021)

N6-Methyladenosine-Related lncRNAs Are Anticipated Biomarkers for Sarcoma Patients
por: Zhang, Xiaohe, et al.
Publicado: (2022)

The N(6)-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2
por: Li, Boyan, et al.
Publicado: (2022)

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression: DUXAP10 contributes to gefitinib resistance by repressing OAS2
por: Ren, Shengnan, et al.
Publicado: (2022)

Predictive Model for Systemic Infection After Percutaneous Nephrolithotomy and Related Factors Analysis
por: Tang, Yiming, et al.
Publicado: (2021)

An N(6)-methyladenosine-associated lncRNA signature for predicting clinical outcome and therapeutic responses in hepatocellular carcinoma
por: Song, Danjun, et al.
Publicado: (2022)

N(6)-methyladenosine-modified lncRNA and mRNA modification profiles in cerebral ischemia-reperfusion injury
por: Shao, Le, et al.
Publicado: (2022)

A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells
por: Porman, Allison M., et al.
Publicado: (2022)

LncRNA AK023948 is a positive regulator of AKT
por: Koirala, Pratirodh, et al.
Publicado: (2017)

The LINK-A lncRNA interacts with PI(3,4,5)P(3) to hyperactivate AKT and confer resistance to AKT inhibitors
por: Lin, Aifu, et al.
Publicado: (2017)

Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer
por: Zhao, Zhan, et al.
Publicado: (2021)

LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA
por: Tang, Jianming, et al.
Publicado: (2018)

EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
por: Pan, Yihui, et al.
Publicado: (2023)

Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma
por: Wang, Yuxin, et al.
Publicado: (2022)

Prediction of prognosis, immune infiltration and immunotherapy response with N6-methyladenosine-related lncRNA clustering patterns in cervical cancer
por: Jia, Haixia, et al.
Publicado: (2022)

LncRNA LINC00961 regulates endothelial-mesenchymal transition via the PTEN-PI3K-AKT pathway
por: Hu, Jin-Xing, et al.
Publicado: (2022)

PDPN(+) CAFs facilitate the motility of OSCC cells by inhibiting ferroptosis via transferring exosomal lncRNA FTX
por: Li, Yaoyin, et al.
Publicado: (2023)

The functions of N6-methyladenosine modification in lncRNAs
por: He, Rong-Zhang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ugitpdm33ku6pm0k247n7lhmnu